Your browser doesn't support javascript.
loading
Expanding U.S. Laboratory Capacity for Neisseria gonorrhoeae Antimicrobial Susceptibility Testing and Whole-Genome Sequencing through the CDC's Antibiotic Resistance Laboratory Network.
Kersh, Ellen N; Pham, Cau D; Papp, John R; Myers, Robert; Steece, Richard; Kubin, Grace; Gautom, Romesh; Nash, Evelyn E; Sharpe, Samera; Gernert, Kim M; Schmerer, Matthew; Raphael, Brian H; Henning, Tara; Gaynor, Anne M; Soge, Olusegun; Schlanger, Karen; Kirkcaldy, Robert D; St Cyr, Sancta B; Torrone, Elizabeth A; Bernstein, Kyle; Weinstock, Hillard.
Afiliação
  • Kersh EN; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA ekersh@cdc.gov.
  • Pham CD; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Papp JR; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Myers R; Maryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
  • Steece R; Tennessee Department of Health, Division of Laboratory Services, Nashville, Tennessee, USA.
  • Kubin G; Texas Department of State Health Service, Austin, Texas, USA.
  • Gautom R; Washington State Public Health Laboratories, Shoreline, Washington, USA.
  • Nash EE; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Sharpe S; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gernert KM; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Schmerer M; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Raphael BH; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Henning T; Antibiotic Resistance Coordination and Strategy (ARX) Unit, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gaynor AM; Association of Public Health Laboratories, Silver Spring, Maryland, USA.
  • Soge O; University of Washington, Seattle, Washington, USA.
  • Schlanger K; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kirkcaldy RD; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • St Cyr SB; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Torrone EA; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Bernstein K; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Weinstock H; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J Clin Microbiol ; 58(4)2020 03 25.
Article em En | MEDLINE | ID: mdl-32024723
ABSTRACT
U.S. gonorrhea rates are rising, and antibiotic-resistant Neisseria gonorrhoeae (AR-Ng) is an urgent public health threat. Since implementation of nucleic acid amplification tests for N. gonorrhoeae identification, the capacity for culturing N. gonorrhoeae in the United States has declined, along with the ability to perform culture-based antimicrobial susceptibility testing (AST). Yet AST is critical for detecting and monitoring AR-Ng. In 2016, the CDC established the Antibiotic Resistance Laboratory Network (AR Lab Network) to shore up the national capacity for detecting several resistance threats including N. gonorrhoeae AR-Ng testing, a subactivity of the CDC's AR Lab Network, is performed in a tiered network of approximately 35 local laboratories, four regional laboratories (state public health laboratories in Maryland, Tennessee, Texas, and Washington), and the CDC's national reference laboratory. Local laboratories receive specimens from approximately 60 clinics associated with the Gonococcal Isolate Surveillance Project (GISP), enhanced GISP (eGISP), and the program Strengthening the U.S. Response to Resistant Gonorrhea (SURRG). They isolate and ship up to 20,000 isolates to regional laboratories for culture-based agar dilution AST with seven antibiotics and for whole-genome sequencing of up to 5,000 isolates. The CDC further examines concerning isolates and monitors genetic AR markers. During 2017 and 2018, the network tested 8,214 and 8,628 N. gonorrhoeae isolates, respectively, and the CDC received 531 and 646 concerning isolates and 605 and 3,159 sequences, respectively. In summary, the AR Lab Network supported the laboratory capacity for N. gonorrhoeae AST and associated genetic marker detection, expanding preexisting notification and analysis systems for resistance detection. Continued, robust AST and genomic capacity can help inform national public health monitoring and intervention.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Gonorreia / Neisseria gonorrhoeae Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Gonorreia / Neisseria gonorrhoeae Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article